Dr. Guy Rouleau, Director of the Montreal Neurological Institute and Hospital -The Neuro, at McGill University and McGill University Health Centre, is being awarded the Prix d’excellence 2014 by the Collège des médecins du Québec, for his outstanding contributions to neurogenetics and medicine. Dr. Rouleau accepts the award today at
Harvard stem cell scientists have discovered that a recently approved medication for epilepsy might be a meaningful treatment foramyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital (MGH) to design an initial clinical trial testing
(Article in French only) Cette découverte liée aux protéines TDP-43 et FUS, présentes à la fois dans la SLA et la démence, pourrait favoriser la mise au point de nouveaux médicaments en plus d’améliorer les effets du riluzole, seul médicament approuvé à ce jour et destiné à freiner la
Mutations in the gene for an enzyme called valosin-containing protein (VCP) are known to directly cause a disease called Inclusion Body Myopathy associated with Paget’s disease of bone and frontotemporal dementia.
More recently, mutations in VCP have been associated with sporadic ALS in some individuals. To examine this association in
Today Biogen Idec reported results from a Phase 3 trial investigating dexpramipexole (dex) in people with amyotrophic lateral sclerosis (ALS). The company said that the trial failed to show slowing of functional decline or improved survival and failed to demonstrate efficacy. Based on these results, the company is discontinuing development